[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633361":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":21,"interventions":31,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":39,"collaborators":11,"id":43,"slug":11,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":11,"eligibilityCriteria":47,"healthyVolunteers":44,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":11,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":11},{"fullName":5,"class":6},"Minia University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Intraoperative Blood Loss",null,"During operation",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"SINGLE",[20],"OUTCOMES_ASSESSOR",[22,27],{"label":23,"type":24,"description":11,"interventionNames":25},"Temporary Uterine Tourniquet Application","ACTIVE_COMPARATOR",[26],"Procedure: Temporary Uterine Tourniquet Application",{"label":28,"type":24,"description":11,"interventionNames":29},"Local Myometrial Epinephrine Injection",[30],"Procedure: Local Myometrial Epinephrine Injection",[32,36],{"type":33,"name":23,"description":34,"armGroupLabels":35,"otherNames":11},"PROCEDURE","The tourniquet will be tightened just enough to achieve visible blanching of the uterus, indicating adequate vascular occlusion, but without excessive tension to avoid tissue damage",[23],{"type":33,"name":28,"description":37,"armGroupLabels":38,"otherNames":11},"Approximately 5-10 mL of the diluted epinephrine will be injected into the myometrium surrounding each fibroid, specifically at the base of the myoma and along the planned incision line, using a laparoscopic injection needle.",[28],{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Mohamed Hassan Mohamed Abdel Ghfar","Lecturer of Obstetrics and Gynecology","100633361",false,"NCT07525687","Temporary Uterine Tourniquet Application Versus Local Myometrial Epinephrine Injection During Laparoscopic Myomectomy","Inclusion Criteria:\n\n* Female patients aged 18-45 years.\n* Diagnosed with symptomatic uterine leiomyomas requiring laparoscopic myomectomy.\n* Presence of at least one myoma with a diameter ≥3 cm and ≤10 cm.\n* Patients with up to 3 myomas (to standardize surgical complexity).\n* Preoperative hemoglobin level ≥10 g\u002FdL.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with more than 3 myomas or any myoma larger than 10 cm.\n* Patients with suspected uterine malignancy (e.g., leiomyosarcoma).\n* Patients with known bleeding disorders or on anticoagulant therapy that cannot be safely discontinued.\n* Patients with significant cardiovascular disease, uncontrolled hypertension, or arrhythmias (relative contraindications for epinephrine).\n* Patients with active pelvic infection.\n* Patients with previous extensive uterine surgery (e.g., multiple prior myomectomies or extensive uterine reconstruction) that may compromise uterine integrity.\n* Patients undergoing concurrent major gynecological procedures that might significantly affect blood loss (e.g., hysterectomy, extensive adhesiolysis).\n* Patients with known allergy to epinephrine.\n* Patients unwilling or unable to comply with follow-up protocols.","FEMALE","18 Years","45 Years",{"count":52,"type":53},37,"ESTIMATED","INTERVENTIONAL",[56],"NA","While both local vasoconstrictors and tourniquet application are recognized methods for blood loss control, there is a paucity of head-to-head randomized controlled trials directly comparing these two distinct approaches in laparoscopic myomectomy. Existing data often compare these methods to no intervention or to other less common techniques. A direct comparison is essential to determine which method offers superior hemostasis with an acceptable safety profile in the laparoscopic setting. This study aims to address this gap in the literature.",[59],"Laparoscopic Myomectomy","NOT_YET_RECRUITING","2026-04-06",{"date":63,"type":64},"2026-04-13","ACTUAL",{"date":66,"type":53},"2026-04-20",{"date":68,"type":53},"2027-01-20",{"name":5,"class":6}]